GuidelineJournal of the American College of Cardiology2026
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Guideline in Journal of the American College of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.Annals of medicine · 2026Article
- SURPASS-CVOT and the Emerging Biology of Cardiometabolic Benefit.Diabetes, obesity & metabolism · 2026Article
- Trends in prevalence of cardiovascular-kidney-metabolic syndrome stages among US young adults, 2011-2020.American heart journal plus : cardiology research and practice · 2026Article
- Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- The Functional Side of Multiple Endocrine Neoplasia Type 1-Associated Adrenal Disease: Mild Autonomous Cortisol Secretion.Diseases (Basel, Switzerland) · 2026Article
- Type 2 Diabetes, Visceral Adiposity, and Carotid Intima-Media Thickness in Hospitalized Adults: A Retrospective Cross-Sectional Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Risk factor obesity: treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Metabolic Indices of Atherogenicity, Insulin Resistance, and Inflammation (AIP, TyG, and CTI) and the Risk of Renal Function Decline in Early-Stage CKM Syndrome: A Nationwide Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Mortality and major comorbidities in coeliac disease: implications for long-term care.Lancet regional health. Americas · 2026Article
- AI-Enabled Echocardiography Identifies an Adverse Epicardial Adiposity Phenotype Associated with Cardiometabolic Dysfunction.medRxiv : the preprint server for health sciences · 2026Article
- Metabolic Health: The Interplay Between NAFLD, MAFLD, MASLD, and Cardiovascular Disease.Life (Basel, Switzerland) · 2026Article
- Molecular Pathways of Cardiometabolic Residual Risk in Type 2 Diabetes: Insulin Resistance, Metaflammation, and Liver-Kidney-Vascular Crosstalk.International journal of molecular sciences · 2026Review
- Review
- Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.Frontiers in endocrinology · 2026Review
- Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?Frontiers in stroke · 2026Article
- A roadmap for heart-liver co-management in MASLD.Military Medical Research · 2026Article
- Serum zinc deficiency and progression of cardiovascular- kidney-metabolic syndrome.Frontiers in nutrition · 2026Article
- A fibrosis-informed refinement of the intermediate-risk stratum for statin allocation: a liver-derived hypothesis anchored to the 2026 PREVENT-based guideline framework.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
Abstract
aimThe "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome" retires, replaces, and expands upon the "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults." The primary intended audience for this guideline is clinicians who care for patients across the spectrum of cardiovascular-kidney-metabolic syndrome, an interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes), chronic kidney disease, and cardiovascular disease.
methodsA comprehensive literature search was conducted from October 29, 2024, to April 14, 2025, to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human subjects that were published since 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to create a living, working document that provides current knowledge in the field of cardiovascular-kidney-metabolic syndrome aimed at all practicing cardiologists, endocrinologists, nephrologists, and primary care and specialty clinicians who manage these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.